Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 23, 2025
Reply
Spencer I Danto, Elena Peeva
Arthritis Research & Therapy
|
December 7, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Spencer I Danto, Negin Shojaee, Ravi Shankar P Singh, et al.
Journal of Clinical Pharmacology
|
September 29, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study
Spencer I Danto, Nikolaos Tsamandouras, Padmalatha Reddy, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
Spencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
Clinical Pharmacology in Drug Development
|
May 4, 2022
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a <sup>14</sup> C-Microtracer Approach
Ravi Shankar P Singh, Martin E Dowty, Mikhail Salganik, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Spencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 12, 2024
Qualified kidney injury biomarkers demonstrate value during early clinical drug development
Kodihalli C Ravindra, Kelly A Fader, David Potter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 23, 2021
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
Aaron Winkler, Weiyong Sun, Saurav De, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 23, 2025
Reply
Spencer I Danto, Elena Peeva
Arthritis Research & Therapy
|
December 7, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Spencer I Danto, Negin Shojaee, Ravi Shankar P Singh, et al.
Journal of Clinical Pharmacology
|
September 29, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study
Spencer I Danto, Nikolaos Tsamandouras, Padmalatha Reddy, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
Spencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
Clinical Pharmacology in Drug Development
|
May 4, 2022
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a <sup>14</sup> C-Microtracer Approach
Ravi Shankar P Singh, Martin E Dowty, Mikhail Salganik, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Spencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 12, 2024
Qualified kidney injury biomarkers demonstrate value during early clinical drug development
Kodihalli C Ravindra, Kelly A Fader, David Potter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 23, 2021
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
Aaron Winkler, Weiyong Sun, Saurav De, et al.
Page
of 1